UMIN000051705
Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer
National Hospital Organization·University Hospital Medical Information NetworkNot yet recruiting
Study focus
- Disease/Condition
- Lung cancer
- Study type
- Observational
Sponsor & location
- Primary sponsor
- National Hospital Organization
- Location
- Japan
Timeline & enrollment
- Phase
- N/A
- Start date
- Sep 30, 2023
- End date
- N/A
ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
- Registry
- University Hospital Medical Information Network
- Trial ID
- UMIN000051705
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for UMIN000051705 through Pure Global AI's free database. This phase not specified trial is sponsored by National Hospital Organization and is currently Not yet recruiting. The study focuses on Lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.